

## Type-2 Isopentenyl Diphosphate Isomerase. Mechanistic Studies with Cyclopropyl and Epoxy Analogues

Jonathan B. Johnston, Joel R. Walker,<sup>‡</sup> Steven C. Rothman, and C. Dale Poulter\*

Department of Chemistry, University of Utah, 315 South 1400 East, RM 2020, Salt Lake City, Utah 84112


Received April 12, 2007; E-mail: poulter@chem.utah.edu

Isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) are the building blocks for biosynthesis of isoprenoid compounds.<sup>1</sup> In Eukarya, Archaea, and some Bacteria, IPP is synthesized from acetate by the mevalonate pathway. Conversion of IPP to DMAPP is catalyzed by IPP isomerase (IDI), a mandatory step that generates the electrophilic allylic moiety required for subsequent prenyl transfer reactions.<sup>2</sup> In other Bacteria and plant chloroplasts, IPP and DMAPP are synthesized from pyruvate and D-glyceraldehyde phosphate in the methylerythritol phosphate pathway.<sup>3</sup> IDI activity, although not required, is typically found in these organisms.


Two forms of IDI are known. Type-1 IPP isomerase (IDI-1), discovered in the 1950s, is a metalloprotein that catalyzes interconversion of IPP and DMAPP by protonation of the carbon-carbon double bond, followed by elimination of a proton from the carbocationic intermediate.<sup>4</sup> A second IPP isomerase (IDI-2) was reported in 2001.<sup>5</sup> The absence of similarities in the amino acid sequences and X-ray structures of IDI-1 and IDI-2 indicate that the two forms of the enzyme evolved independently.<sup>6</sup> Like IDI-1, IDI-2 requires divalent magnesium, presumably for binding the diphosphate moieties of the substrates.<sup>7</sup> However, IDI-2 is a flavoprotein, and NADPH or other suitable reducing agents are required to reduce the FMN cofactor to generate the catalytically competent form of the enzyme.<sup>8</sup> Although FMN is typically associated with oxidation-reduction chemistry, there are examples of flavins participating in isomerizations, with transient changes in oxidation states.<sup>9</sup>

Two mechanisms have been proposed for the isomerization catalyzed by IDI-2: a proton addition-elimination mechanism similar to IDI-1<sup>7,9</sup> and a hydrogen atom addition-elimination in which reduced FMN donates a hydrogen atom to generate a transient semiquinone/substrate radical pair<sup>9,10</sup> (Scheme 1). We synthesized cyclopropyl (cIPP, X = CH<sub>2</sub>) and epoxy (oIPP, X = O) analogues as mechanism-based inhibitors of IDI-2 in an effort to distinguish between these two possible mechanisms. Potential reactions of the two compounds in proton-initiated and hydrogen-atom-initiated scenarios for the mechanism of isomerization of IPP by IDI-2 are shown in Scheme 2. Proton-initiated isomerization could lead to inhibition with cIPP by nucleophilic attack at the cyclopropane ring of the cyclopropylcarbanyl cationic intermediate<sup>11</sup> in analogy to the inactivation of IDI-1 by vinyl-IPP derivatives,<sup>12</sup> while protonation of the oxirane ring in oIPP could inactivate the enzyme by nucleophilic attack at the activated epoxide by a nucleophile in the active site similar to irreversible inhibition by epoxide analogues previously reported for IDI-1.<sup>13</sup> Hydrogen-atom-initiated isomerization would generate cyclopropylcarbanyl<sup>14</sup> or epoxy carbanyl radicals,<sup>15</sup> which could isomerize to their allylic counterparts and inactivate the enzyme through hydrogen abstraction or recombination reactions.

**Scheme 1.** Proton (top) and Hydrogen Atom (bottom) Addition-Elimination Mechanisms Proposed for IDI-2




**Scheme 2.** Potential Reactions for Mechanism-Based Inhibition of IDI-2 by cIPP (X = CH<sub>2</sub>) and oIPP (X = O)



A 2.5 mM solution of cIPP in 50 mM Na<sub>2</sub>HPO<sub>4</sub> buffer at 37 °C, pH 7.2, containing 2 mM NADPH was incubated with IDI-2 from *Thermus thermophilus*, and the course of the reaction was followed by <sup>1</sup>H NMR spectroscopy. Over a period of 5 h, the cyclopropyl analogue isomerized to its allylic isomer, which was unstable to the incubation conditions and solvolyzed to give a rearranged tertiary vinyl alcohol as shown in Scheme 3. The cIPP did not

**Scheme 3.** IDI-2-Catalyzed Isomerization of cIPP and Spontaneous Solvolysis of cDMAPP



inhibit IDI-2 in a time-dependent irreversible manner when preincubated with the enzyme. In contrast, preincubation of IDI-2 with oIPP at 37 °C, pH 7.0, resulted in rapid, time-dependent first-order inactivation of the enzyme. A double reciprocal plot of the rate of inactivation versus [oIPP] gave  $k_{\text{inact}} = 0.37 \pm 0.07 \text{ min}^{-1}$  and  $K_1$

<sup>‡</sup> Current address: AMRI, 26 Corporate Cir., P.O. Box 15098, Albany, NY 12212.

$= 1.4 \pm 0.3 \mu\text{M}$ . The enzyme was not inactivated during a control experiment without NADPH in the buffer.

In a large-scale inactivation experiment, flavin-bound IDI-2 was incubated with oIPP. The sample was analyzed by RP-HPLC on a  $C_{18}$  column with UV detection and by negative ion electrospray HPLC-MS. Samples introduced by directed infusion were also analyzed by negative ion mode electrospray-MS. A peak was seen at  $m/z$  731 in both the LC-MS and direct infusion experiments, consistent with formation of a covalent adduct between reduced FMN and oIPP. The peak at  $m/z$  731 was also accompanied by peaks at  $m/z$  456 and 274, apparently from a fragmentation of the oIPP-flavin adduct. Control experiments with IPP or without substrate instead of oIPP gave an ESI peak at  $m/z$  455 for oxidized FMN. When enzyme that had been incubated with IPP was washed under aerobic conditions, the sample gave a UV-vis spectrum characteristic of oxidized FMN.<sup>8</sup> In contrast, enzyme inhibited with oIPP gave a spectrum consistent with a modified flavin (see Supporting Information). In addition, a transient absorbance was seen at 600 nm during guanidinium-HCl denaturation and ultrafiltration. Similar behavior was previously attributed to a semi-quinone intermediate during the oxidation of N5 flavin adducts.<sup>16</sup>

To further delineate the mechanism for inhibition by oIPP, parallel inactivation experiments were carried out in  $D_2O$  and  $H_2O$  buffers. In parallel experiments, samples of the enzyme were prepared in Tris buffer, pH 7.8 ( $H_2O$ ) or pD 7.8 (99%  $D_2O$ ), both containing NADPH. The mixtures were preincubated without inhibitor for 5 min to reduce bound FMN before addition of oIPP or IPP and then were incubated for 2 h. Following the incubations, the samples were washed under aerobic conditions in  $H_2O$  buffer and analyzed in protic solvents.

If oIPP were activated by addition of a proton or a hydrogen atom to the double bond of oIPP, the hydrogen would be retained in the oIPP-FMN adduct, and the oIPP-FMN adduct generated by inactivation of IDI-2 in  $D_2O$  buffer would contain at least one atom of deuterium. Conversely, inactivation of IDI-2 initiated by protonation of the epoxide moiety in oIPP in  $D_2O$ , followed by exchange in a protic solvent, would not result in deuterium incorporation into the final adduct. Negative ion electrospray mass spectra for the oIPP-FMN adducts from incubations in  $H_2O$  and  $D_2O$  gave a peak at  $m/z$  731, demonstrating the absence of deuterium incorporation (see Supporting Information). This result is consistent with protonation of the epoxide oxygen in oIPP, followed by ring opening. There is no evidence for rearrangement of cyclopropylcarbinyl or epoxy-carbinyl radicals from cIPP or oIPP, which are well-documented radical "clocks" with rearrangement rates of  $\sim 1.3 \times 10^8$  and  $3.2 \times 10^{10} \text{ s}^{-1}$ ,<sup>14,15</sup> respectively. Our results with oIPP are similar to those recently reported for IPP epoxide, a mechanism-based inhibitor of type-1 IPP isomerase,<sup>13</sup> where high concentrations of the inhibitor irreversibly inhibit IDI-2 with concomitant formation of a covalent adduct with the flavin cofactor.<sup>17</sup>

In conclusion, we have established that oIPP is a potent active-site-directed, irreversible inhibitor of IDI-2. The enzyme catalyzes formation of a stable covalent adduct between oIPP and FMNH<sub>2</sub> in a reaction catalyzed by protonation of the epoxide moiety in oIPP followed by nucleophilic addition of the cofactor. At this point,

the structure of the adduct has not been established, although the UV-visible spectrum and the mass spectral fragmentation patterns are consistent with addition of the inhibitor to the N5 nitrogen of the isoalloxazine ring in FMN. These results suggest that isomerization by IDI-2 involves protonation of the substrates in a manner similar to the reaction catalyzed by IDI-1. It is evident from our inactivation studies that the reduced flavin resides in close proximity to bound substrate, where it can potentially provide a function critical to catalysis. Isomerization of cIPP to cDMAPP indicates that a tertiary cyclopropylcarbinyl radical, generated by hydrogen transfer to cIPP from FMNH<sub>2</sub> or by single electron transfer (SET) from FMNH<sup>-</sup> to a tertiary cyclopropylcarbinyl cationic intermediate, is not an intermediate or hydrogen atom transfer from FMNH<sup>-</sup> to the intermediate cyclopropylcarbinyl radical is substantially faster than the cyclopropylcarbinyl to homoallyl radical rearrangement. At this point, the exact role of the flavin cofactor has not been established.

**Acknowledgment.** J.B.J. was supported by NIH pre-doctoral training grant GM 08537. S.C.R. was supported by NIH post-doctoral fellowship GM 071114. This work was also funded by NIH grant GM 25521. We wish to thank Drs. E. Rachlin and J. Muller for assistance with mass spectrometry experiments.

**Supporting Information Available:** NMR spectra for conversion of cIPP to cDMAPP. Experimental details for large-scale inactivation experiments. LC-MS chromatogram with ESI for the flavin adduct. ESI spectra for oIPP/flavin adducts formed in  $H_2O$  and  $D_2O$ . Spectra of enzyme complexes following incubation and following guanidinium-HCl denaturation. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) Thulasiram, H. V.; Erickson, H. K.; Poulter, C. D. *Science* **2007**, *316*, 73–76.
- (2) Kuzuyama, T.; Seto, H. *Nat. Prod. Rep.* **2003**, *20*, 171–183.
- (3) Rohmer, M. In *Comprehensive Natural Products Chemistry*; Cane, D. E., Ed.; Pergamon Press: New York, 1999; Vol. 2, pp 45–67.
- (4) (a) Carrigan, C. N.; Poulter, C. D. *J. Am. Chem. Soc.* **2003**, *125*, 9008–9009. (b) Lee, S.; Poulter, C. D. *J. Am. Chem. Soc.* **2006**, *128*, 11545–11550. (c) Ramos Valdivia, A. C.; van der Heijden, R.; Verpoorte, R. *Nat. Prod. Rep.* **1997**, *14*, 591–603.
- (5) Kaneda, K.; Kuzuyama, T.; Takagi, M.; Hayakawa, Y.; Seto, H. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 932–937.
- (6) (a) de Ruyck, J.; Rothman, S. C.; Poulter, C. D.; Wouters, J. *Biochem. Biophys. Res. Commun.* **2005**, *338*, 1515–1518. (b) Steinbacher, S.; Kaiser, J.; Gerhardt, S.; Eisenreich, W.; Huber, R.; Bacher, A.; Rohdich, F. *J. Mol. Biol.* **2003**, *329*, 973–982.
- (7) Laupitz, R.; Hecht, S.; Amslinger, S.; Zepeck, F.; Kaiser, J.; Richter, G.; Schramek, N.; Steinbacher, S.; Huber, R.; Arigoni, D.; Bacher, A.; Eisenreich, W.; Rohdich, F. *Eur. J. Biochem.* **2004**, *271*, 2658–2669.
- (8) Rothman, S. C.; Helm, T. R.; Poulter, C. D. *Biochemistry* **2007**, *46*, 5437–5445.
- (9) Bornemann, S. *Nat. Prod. Rep.* **2002**, *19*, 761–772.
- (10) Hemmi, H.; Ikeda, Y.; Yamashita, S.; Nakayama, T.; Nishino, T. *Biochem. Biophys. Res. Commun.* **2004**, *322*, 905–910.
- (11) Poulter, C. D.; Winstein, S. *J. Am. Chem. Soc.* **1970**, *92*, 4282–4288.
- (12) Wu, Z.; Wouters, J.; Poulter, C. D. *J. Am. Chem. Soc.* **2005**, *127*, 17433–17438.
- (13) Xiang, J. L.; Christensen, D. J.; Poulter, C. D. *Biochemistry* **1992**, *31*, 9955–9960.
- (14) Griller, D.; Ingold, K. U. *Acc. Chem. Res.* **1980**, *13*, 317–323.
- (15) Krishnamurthy, V.; Rawal, V. H. *J. Org. Chem.* **1997**, *62*, 1572–1573.
- (16) Ghisla, S.; Massey, V.; Choong, Y. S. *J. Biol. Chem.* **1979**, *254*, 10662–10669.
- (17) Hoshino, T.; Tamegai, H.; Kakinuma, K.; Eguchi, T. *Bioorg. Med. Chem.* **2006**, *14*, 6555–6559.

JA072501R